🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion

CTRIAL-IE 16-12

Phase 3 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion for High risk resected melanoma. is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
High risk resected melanoma.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials